Investors and Advisors
Dr Allison Jeynes
Chief Executive Officer
- UK MD with over 25 years of senior leadership experience in the pharmaceutical industry.
- Significant global drug development experience and successful EU and US drug approvals across a range of therapeutic areas.
- Leadership of global clinical development teams for Phase 3, including CRO selection and management.
- Strong networks within the pharma industry and relevant regulatory bodies.
Chief Financial Officer
- Chartered Accountant and Finance Professional with 20 + years of experience at KPMG and in the Biotech/Pharma sector.
- Business partner to global research and development supporting development, approval and launch of blockbuster products for neurology and immunology indications.
- Leadership of global functions including Portfolio Management and Integration.
- Non-Executive Director and Audit Committee Chair of AIM listed CRO.
Dr Mark Weinberg
Chief Medical Officer
- US MD with 17+ years of experience in pharma and biotech.
- Experience throughout the development cycle, leading matrixed development teams in several therapeutic areas.
- US and EU regulatory experience ranging from pre-IND through NDA/BLA interfaces.
- MBA and Management experience ranging from vendor oversight in a micro-cap biotech to leadership of >200 person department in mid-size pharma.
Dr Laurence Reilly
Vice President & Chief Scientific Officer
- UK MD with significant clinical development experience in phases I-IV.
- Previously held roles in large pharma at both Pfizer & Lundbeck, in addition to mid-size biotech and medical device experience.
- Medical degree from the University of Liverpool (UK).
- Masters degree in Law, with postgraduate research focus in Medical Law and Ethics.
Vice President Clinical Development
- 20 years in large pharma and biotech industry, holding key positions as Director of Clinical Operations.
- Dedicated to the development and execution of clinical strategies, clinical and operational implementation of a range of complex compound programmes and the governance and management of pharma and CRO partners.
- A champion of continuous process improvement putting quality at the centre of all clinical operations activities she leads.
- Extensive experience in global clinical study management, with prior management positions at Amgen and Eli Lilly.
- Substantial clinical development experience with wide therapeutic expertise including oncology, endocrinology and haematology.
- PhD in Biological Sciences from the University of Bath and a BSc (1st Class) from the University of Edinburgh.
- 30 years in pharmaceutical industry.
- Global regulatory leadership positions in Pfizer, AstraZeneca and GE Healthcare.
- Expertise in regulatory for global drug development and delivery of multiple new drug approvals worldwide.
- Member of NDA Regulatory Advisory Board (consulting firm).
- Joined Lundbeck in June 2008, after working with the American medical corporation Wyeth/Lederle for 27 years, most recently as President of Wyeth Europe and Wyeth BioPharma.
- Presently a board member of Alfa Laval, UCB, Agenus and is the chairman for Hansa Medical.
- Advisor to Nestle Health Science.
Partner - Abingworth
- Joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) as a Managing Director in the European Equity Research Group.
- Worked at CSFB’s Health Care Group in the Investment Banking Division in New York, as well as a pediatrician in Melbourne, Australia.
- Current and past directorships include Gensight, Healthcare Brands International, Novexel, Solexa, Synosia, Syntaxin and Wilson Therapeutics.
- Medical degree from the University of Liverpool (UK); PhD in clinical pharmacology from the University of Melbourne, Australia; and MBA from Harvard Business School.
- Focused on exits of Abingworth’s venture investments via M&A and IPOs, and venture investments in Europe.
KURT C. WHEELER
Managing Director - Clarus Ventures
- Managing Director of Clarus Ventures since the firm’s inception in 2005 after being a General Partner at MPM Capital, a healthcare venture capital firm.
- Over 30 years of direct investment and industry experience within the healthcare sector.
- Founder and CEO of InControl, a medical device company sold to Guidant, previously he was a Principal with the Mayfield Fund focused on healthcare investing.
- BA from Brigham Young University, and a MBA from Northwestern University’s Kellogg School.
- Represents Clarus Ventures on the Board of Directors of Globus (NYSE:GMED), Flowonix, SFJ Pharmaceutical and Avillion LLP.
- Prior Investments include Hemosense acquired by Inverness Medical, Intrathrerapeutics acquired by Sulzer Medica, Eyetech Pharmaceuticals, SenoRx acquired by CR Bard, Neuromed Pharmaceuticals, CHF Solutions acquired by Gambro, Somaxon Pharmaceuticals and Zogenix.
Executive Vice President, Head of Research & Investments – Royalty Pharma
- Joined Royalty Pharma in July 2008 after twelve years on Wall Street as a biotechnology analyst.
- Prior to joining Royalty Pharma he was Managing Director and Head of Healthcare Equity Research at Friedman Billings Ramsey.
- Previously worked at Bank of America and CIBC World Markets Corp (now Oppenheimer & Co).
- Holds a BA from Furman University and a PhD in biochemistry and molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.
TED W. LOVE
Chief Executive Officer – Global Blood Therapeutics
- Chief Executive Officer at Global Blood Therapeutics and former Executive Vice President and Head of Research & Development at Onyx Pharmaceuticals and Chairman of the Board of Directors of Nuvelo Inc. after joining from Theravance, Inc., where he served as Senior Vice President of Development.
- Spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development.
- Serves as a member of the boards of directors of KaloBios, Oncothyreon and Amicus Therapeutics. Served for six years on the California Independent Citizens’ Oversight Committee (ICOC) that oversees the $3 billion allocated to stem cell research authorized by Proposition 71.
- Bachelor’s degree in molecular biology from Haverford College, Medical Degree from Yale Medical School, completing his training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School.
The Investors and Advisors listed above are Directors of Bond 2 Development 2 GP Ltd, the General Partner of Bond Avillion 2 Development LP, who has entered into co-development agreements with Pharma.